Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors

PURPOSE: Combining cytotoxic agents with bevacizumab has yielded significant benefits in a number of solid tumors. Combining small-molecule kinase inhibitors of VEGFR with chemotherapy has yet to demonstrate clinical benefit. The dose, schedule and agents used may be critical to the development of t...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Brell, Joanna M., Krishnamurthi, Smitha S., Rath, Linda, Bokar, Joseph A., Savvides, Panayiotis, Gibbons, Joseph, Cooney, Matthew M., Meropol, Neal J., Ivy, Percy, Dowlati, Afshin
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2012
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4199746/
https://ncbi.nlm.nih.gov/pubmed/22868341
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-012-1936-5
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller